CLK2 Expression Is Associated with the Progression of Colorectal Cancer and Is a Prognostic Biomarker

Table 2

Logistic regression of ARMCX1 expression and clinicopathologic parameters in TCGA and our validation cohort.

Clinical features		TN	OR	95% CI	value
TCGA cohort
Age	≥65 vs. <65	534	1.387	0.981-1.963	0.064
Gender	Female vs. male	534	0.707	0.502-0.994	0.046
Radiation therapy	Yes vs. no	534	0.853	0.447-1.616	0.626
Chemotherapy	Yes vs. no	534	1.098	0.777-1.555	0.596
Local invasion	T2 vs. T1	113	1.435	0.533-4.011	0.478
	T3 vs. T1	384	1.762	0.693-4.828	0.245
	T4 vs. T1	75	8.242	2.407-38.475	0.002
LN metastasis	Yes vs. no	532	0.965	0.640-1.453	0.865
Distant metastasis	Yes vs. no	479	1.204	0.744-1.954	0.450
TNM stage	Stage II vs. stage I	291	1.446	0.883-2.378	0.144
	Stage III vs. stage I	257	1.696	1.018-2.846	0.044
	Stage IV vs. stage I	174	1.592	0.875-2.915	0.129
Validation cohort
Age	≥65 vs. <65	50	1.379	0.453-4.264	0.571
Gender	Female vs. male	50	0.375	0.098-1.286	0.129
Grade	G3 vs. G1 + G2	50	3.188	1.023-10.602	0.781
Tumor size	≥5 cm vs. <5 cm	50	1.909	0.626-6.023	0.050
Local invasion	T4 vs. T1 + T2 + T3	50	6.729	2.035-25.083	0.003
LN metastasis	Yes vs. no	50	3.500	0.971-14.781	0.066
TNM stage	Stage III vs. stage I/II	50	3.500	0.971-14.781	0.066

Abbreviations: OR: odds ratio; TN: total number; CI: confidence interval; LN: lymph node.